01—Abstract
Summary
Summary of the 8-K filed August 15, 2024. Cited figures are marked; the original filing is the authoritative source.
Cencora, Inc. (NYSE: COR) filed an 8-K on August 15, 2024 to announce a board appointment rather than a financial or operational event.
The Board appointed Frank Clyburn as an independent director on August 13, 2024, effective October 1, 2024. With his seat and the previously disclosed appointment of Robert P. Mauch, the Board expands from eleven to thirteen members.
The filing contains no financial results, guidance, or material transactions. Mr. Clyburn's compensation will mirror that of other non-employee directors under the company's policy described in its January 29, 2024 proxy statement, including the annual equity award, prorated from October 1, 2024 through the 2025 Annual Meeting of Stockholders. The company states there are no arrangements tying him to the appointment, no family relationships with directors or executives, and no related-party transactions requiring disclosure under Item 404(a) of Regulation S-K.
For investors, the significance is mainly governance-related. Mr. Clyburn brings senior pharmaceutical experience, including a prior role as Executive Vice President and President of Human Health at Merck, and recent CEO experience at International Flavors and Fragrances.
The company framed the addition as supporting its pharmaceutical-centric strategy and long-term, sustainable growth. The board expansion itself is modest and unlikely to affect near-term valuation.
02—Key points
Key Highlights
- Board appointed Frank Clyburn as an independent director, effective October 1, 2024, expanding the Board from eleven to thirteen members alongside Robert P. Mauch's appointment.
- Clyburn's background includes recent CEO and board service at International Flavors and Fragrances Inc. and senior pharmaceutical leadership, including EVP and President of Human Health at Merck.
- Director compensation follows the standard non-employee director policy, with the annual equity award prorated from October 1, 2024 to the 2025 Annual Meeting.
- The company disclosed no related-party transactions, family relationships, or undisclosed arrangements tied to Clyburn's appointment.
- Management tied the appointment to Cencora's pharmaceutical-centric strategy and its focus on long-term, sustainable growth.
- The filing contains no financial results, guidance, or material transactions, so it has limited direct impact on near-term financial performance.
- The press release describes Cencora as a leading global pharmaceutical solutions organization with more than $250 billion in annual revenue.
03—Questions
Frequently Asked Questions
Who is Frank Clyburn and why was he appointed to Cencora's board?
Frank Clyburn is a senior executive with decades of pharmaceutical industry experience, including EVP and President of Human Health at Merck, and most recently CEO and board member of International Flavors and Fragrances Inc. Cencora said his experience will help as it focuses on its pharmaceutical-centric strategy and long-term growth.
When does Mr. Clyburn's board service begin?
His appointment takes effect October 1, 2024, the same date Robert P. Mauch's appointment becomes effective, at which point the Board grows from eleven to thirteen members.
How will Mr. Clyburn be compensated?
He will receive the same compensation and benefits as other non-employee directors under Cencora's policy described in its January 29, 2024 proxy statement. This includes the annual equity award, prorated from October 1, 2024 through the 2025 Annual Meeting of Stockholders.
Does this appointment signal anything about Cencora's financial outlook?
No. The filing contains no financial results, guidance, or material transactions. It is a governance update, and it is unlikely to affect near-term financial performance on its own.
Are there any conflicts of interest or related-party concerns with Mr. Clyburn?
The company states there are no arrangements or understandings tied to his appointment, no family relationships with any director or executive officer, and no transactions requiring disclosure under Item 404(a) of Regulation S-K.
04—Continue